Adderall XR Cost in Montana 2026: Cash Price, Insurance, and Compounded Options

What This Page Can and Can't Tell You About Price

There is no single "Adderall XR cost in Montana." The manufacturer's list price, the price a pharmacy benefit manager negotiates, the price a discount-card network contracts for, and the price an individual pharmacy charges walk-in cash customers are four different numbers that move independently and change without notice. Reporting one figure as "the" Montana price risks being wrong the day someone reads it.

What can be stated with confidence: generic mixed amphetamine salts XR is off-patent, has multiple manufacturers, and cash-pay prices with a discount card are routinely well below the brand list price nationally. Discount aggregators like GoodRx publish real-time pharmacy-level pricing, and checking a specific pharmacy the same day you plan to fill is the only reliable way to know your actual cost. If you were quoted a specific dollar figure for Montana pricing, verify it against a live pharmacy quote or discount-card app rather than treating any number in an article as current.

A drug shortage for amphetamine-based stimulants that began in 2022 has affected supply intermittently since. The FDA maintains a live drug shortage database that shows current status by product and strength; shortages can push cash prices up temporarily at pharmacies with low stock, so checking a couple of local pharmacies is practical advice regardless of what the "typical" price is reported to be.

Montana Medicaid and Adderall XR

Sources reviewed for this article describe Adderall XR as excluded from Montana Medicaid's preferred drug list, with prior authorization exceptions rarely granted for the extended-release formulation. That claim was not confirmed against Montana's current, published Medicaid preferred drug list, and state formularies are revised on a regular cycle. Anyone relying on this for a real coverage decision should ask the prescriber's office to check the live Montana Medicaid formulary, or call the plan directly, rather than trusting a static claim on this page.

For children with ADHD who depend on Medicaid, formulary exclusions matter clinically. A large, federally funded 14-month trial (the MTA Cooperative Group study, published in Archives of General Psychiatry in 1999) found that carefully managed medication treatment produced larger reductions in ADHD symptoms than behavioral therapy alone or routine community care. The study is indexed at PubMed. That finding supports why access to an appropriate stimulant matters, but it is evidence about treatment efficacy, not a Montana coverage rule, and it should not be read as guaranteeing coverage or predicting a specific patient's outcome.

If a claim is denied, a formal exception or grievance process is generally available through the Medicaid managed care organization. A letter of medical necessity documenting functional impairment and any prior treatment trials is the standard basis for that appeal; a prescriber's office handles the specifics.

Commercial Insurance and Prior Authorization

Commercial plans, including ACA marketplace and employer-sponsored plans, commonly require prior authorization for the extended-release formulation and may require documentation of the diagnosis, prior medication trials, and confirmation that the requested dose falls within FDA labeling. The FDA-approved dosing range for Adderall XR is 20 mg to 30 mg per day for adults with ADHD, with pediatric dosing titrated in smaller increments starting around 5 mg to 10 mg for children age 6 and older. The current FDA prescribing information describes this dosing range, though the exact document should be verified directly with the FDA before relying on it.

Step therapy, where an insurer requires a documented trial of an immediate-release stimulant before approving the extended-release version, is a common commercial-plan practice, though whether a specific Montana plan applies it, and how long that process takes, depends on the plan. A step-therapy override request is the standard path when a patient has a documented intolerance or a prior failed trial; this is a matter for the prescriber's office and the specific plan, not something this page can predict.

Reported commercial copays for the generic have ranged roughly $10 to $45 per month in the sources reviewed, with high-deductible plans sometimes charging closer to the negotiated cash rate until the deductible is met. Treat any copay figure as an estimate only; your plan's summary of benefits is the authoritative source.

Compounded Mixed Amphetamine Salts: What's Legal

Compounded mixed amphetamine salts can legally be prepared and dispensed by a licensed 503A compounding pharmacy under a valid, patient-specific prescription, subject to state pharmacy board oversight and the federal Drug Quality and Security Act. A 503A pharmacy compounds for an individual patient against an individual prescription; this is a different legal category from a 503B outsourcing facility, which manufactures in bulk without a patient-specific prescription requirement.

Amphetamine remains a DEA Schedule II substance regardless of whether it's compounded or manufactured, so the same controlled-substance rules apply: no refills, a prescription that is written or transmitted electronically under EPCS rules, and typically a 30-day supply limit per fill.

Verification Checklist: Stable Facts vs. Facts That Change

Before acting on anything in this article, or repeating it to a patient, separate what's fixed in federal regulation or clinical evidence from what depends on today's date, your specific plan, or a specific pharmacy.

Stable, federal approval and clinical facts that don't change month to month:

• FDA-approved indications: ADHD and narcolepsy, age 6 and older
• FDA labeled adult dosing: 20 mg starting dose, 30 mg per day maximum
• DEA Schedule II classification and the baseline rules that come with it (no refills, EPCS or written prescription, supply-limit norms)
• The 503A versus 503B legal distinction for compounding pharmacies
• The existence and general direction of the MTA trial evidence supporting medication management for ADHD

Date-sensitive, verify before you rely on it or repeat it to someone:

• Whether Adderall XR is currently on Montana Medicaid's preferred drug list (check the current MT DPHHS formulary or call the plan)
• Any specific cash price at any specific pharmacy (check a live discount-card quote the day of fill)
• Whether current DEA telehealth flexibilities allow Schedule II prescribing without a prior in-person visit (this framework has been extended and modified repeatedly; check the DEA's current guidance)
• A specific insurer's prior authorization or step-therapy criteria and copay amount (check the plan's current formulary and summary of benefits)
• Current drug shortage status for amphetamine products (check the FDA shortage database)
• Pricing or eligibility at a specific 340B/FQHC site or compounding-pharmacy membership program (contact the site directly)
• Manufacturer patient assistance program income thresholds and enrollment rules (check the current program page)

If a fact falls in the second list and you can't verify it against a current source, treat any number attached to it as an estimate, not a quote.

Telehealth Prescribing of Schedule II Stimulants

Federal rules governing telehealth prescribing of Schedule II controlled substances, including Adderall XR, have been subject to a series of temporary extensions rather than a single settled framework, and the exact requirements in effect on any given date should be confirmed rather than assumed. In general, some telehealth pathways for established patients have existed under DEA flexibilities, and DEA electronic prescribing (EPCS) requirements apply regardless of whether the visit was in person or by telehealth. Whether a Montana patient can currently get a first-time or renewal Adderall XR prescription through telehealth without an in-person visit depends on the current DEA rule status and the individual prescriber's registration, and should be confirmed with the prescribing platform directly.

Professional medical associations have generally published positions supporting telehealth access, including for populations facing distance barriers to specialist care. That is a general policy stance, not a guarantee of what any specific telehealth platform can currently prescribe in Montana.

Why List Price and Cash Price Diverge

Manufacturer list prices, insurer-negotiated net prices, and discount-card contract prices operate on different layers of the drug pricing system, which is why a brand list price near $260 per month can coexist with generic cash prices reported well under $50. Generic competition is the main driver: once a drug is off-patent with multiple manufacturers, cash and discount-card pricing tends to fall well below any list price, which functions mainly as a starting point for rebate negotiations between manufacturers and pharmacy benefit managers rather than as a price any typical patient actually pays.

Net prices insurers pay after rebates aren't publicly disclosed. Aggregate manufacturer pricing data reported to CMS under the Medicaid Drug Rebate Program is public and is one way to see that generic stimulant pricing sits low relative to brand pricing, though it doesn't tell you what a specific Montana pharmacy will charge on a specific day. CMS Medicaid Drug Rebate Program information is at medicaid.gov.

The practical takeaway: a cash-paying patient should check a discount-card price before paying whatever a pharmacy quotes without one. Discount-card rates are frequently well below an uninsured "list" cash price at the same counter.

Assistance Programs Worth Checking

Manufacturer and general patient assistance. Because generic mixed amphetamine salts XR dominates the market, dedicated manufacturer coupons for the branded product are limited, but income-qualified patient assistance programs exist for some branded stimulants. NeedyMeds maintains a directory of current programs.

Discount-card networks. GoodRx and similar services are not insurance; they're contracted discount rates with participating pharmacies. Most major chains and many independents accept them. Check the app for a current, pharmacy-specific quote rather than relying on a remembered or reported price.

340B pharmacies at federally qualified health centers. FQHCs participating in the 340B drug pricing program can offer meaningfully discounted pricing to patients who receive care there. Program details are at hrsa.gov. Whether a specific Montana FQHC's pharmacy passes 340B pricing through to a specific patient, and at what price, is a question for that clinic.

CHIP formulary exceptions. Some state CHIP programs handle formulary exceptions differently than standard Medicaid. A pediatric prescriber familiar with Montana's current CHIP rules is the right resource for a specific child's case.

Clinical Context: Why Extended-Release Instead of Immediate-Release

Adderall XR uses a dual-release capsule designed to release a portion of the dose immediately and the remainder several hours later, intended to extend symptom coverage across the day from a single morning dose, compared with immediate-release formulations that typically require two or three daily doses. This mechanism is described in FDA prescribing information for the product. Twice- or three-times-daily dosing raises the number of points where a dose can be missed and can produce a rebound of symptoms as an earlier dose wears off.

A meta-analysis comparing Adderall-type and methylphenidate-type stimulants found both classes effective for ADHD symptoms, without establishing one as uniformly superior for all patients. The analysis is indexed at PubMed. Professional guidance from child and adolescent psychiatry has supported stimulant medication as part of a comprehensive ADHD treatment approach. The AACAP practice parameter is indexed at PubMed. Which formulation and dose is appropriate for a given patient is an individualized clinical decision that this page cannot make; it depends on symptom pattern, prior response, comorbidities, and cardiovascular history, among other factors.

What to Expect Starting Treatment

Adults typically start at the labeled 20 mg dose. The FDA label calls for monitoring blood pressure and heart rate at baseline and with dose changes, and cardiology clearance is generally advised before starting an amphetamine product in someone with pre-existing hypertension or known structural heart disease. Reported side effects in this drug class commonly include appetite suppression and sleep disruption if taken later in the day; a treating clinician can describe the expected magnitude and timeline for a specific patient, which this page should not attempt to quantify precisely without pulling the exact label language.

If the starting dose isn't sufficient, dose increases (commonly to 25 mg or 30 mg) happen over subsequent visits within the FDA-labeled maximum of 30 mg per day for adults. Each dose change can require a new prior authorization if the insurer's approval was tied to a specific strength, which is a process question for the prescriber's office and the plan.

When to Seek Urgent Care

Chest pain, fainting, significant shortness of breath, signs of an allergic reaction, or new psychiatric symptoms such as hallucinations after starting or increasing a stimulant warrant urgent evaluation rather than waiting for a routine follow-up. This is general safety guidance, not a substitute for a clinician's assessment of a specific patient's symptoms.